Gentian Diagnostics signs distribution agreement for Cystatin C
23. Aug 2022 |
3 min read
Gentian Diagnostics ASA, a fast-growing developer and manufacturer of innovative and efficient diagnostics, has entered into a distribution agreement for the Gentian Cystatin C Immunoassay with a global diagnostics company. The cooperation is positioned towards the diagnosis and treatment of renal disease, with launch scheduled for the second half of 2022, initially in the USA and Canada.
“We are pleased to experience increasing demand for Cystatin C as a superior marker for diagnosis and treatment of renal disease, particularly in the US market,” says CEO Hilja Ibert from Gentian Diagnostics.
Gentian’s commercial strategy is to secure broad roll-out and acceptance of its products, which requires distribution through global diagnostics companies.
“This distribution agreement for Cystatin C confirms the attractive clinical benefits of our product and Gentian’s ability to establish commercial partnerships worldwide, adds Ms. Ibert.
Gentian’s new distributor develops and distributes in vitro diagnostic systems mainly destined for biological analysis in medical laboratories on a worldwide basis. These automated analysers meet the needs of various users including private laboratories, clinics and university hospitals.
While the clinical use of Cystatin C can have far-reaching benefits across all patient groups, certain vulnerable patient populations may experience a greater benefit. Some specific patient groups would receive more accurate results with Cystatin C because its concentrations are independent of muscle mass and show less age and gender-related variation relative to creatinine.
Previously, Gentian has outlined the roadmap for its portfolio of high-impact diagnostics tests which supports the company’s revenue growth ambitions. The company expects Cystatin C to remain a key value driver in the realisation of this growth roadmap and confirming clinical relevance and entering global commercial partnerships are key enablers.
About Gentian Diagnostics Gentian Diagnostics (OSE: GENT), founded in 2001, develops and manufactures high-quality, in vitro diagnostic reagents. Gentian’s expertise and focus lies within immunochemistry, specifically infections, inflammations, kidney failures and congestive heart failures. By converting existing and clinically relevant biomarkers to the most efficient automated, high-throughput analysers, the company contributes to saving costs and protecting life. Gentian is based in Moss, Norway, serving the global human and veterinary diagnostics markets through sales and representative offices in Sweden, USA and China. For more information, please visit www.gentian.com.